What is CNTB (CNTB) stock price today?

CNTB (CNTB) is currently trading at $2.07, down 1.67% today.

What is CNTB P/E ratio?

CNTB's P/E ratio is -2.31. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CNTB return on equity (ROE)?

CNTB's return on equity (ROE) is -130.95%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CNTB's market cap?

CNTB has a market capitalization of $130.02M.

NASDAQ · Biotechnology

CNTB (CNTB) Stock

$2.07 -1.67% NASDAQ: CNTB Healthcare

Valuation

Metric	Value
Price	$2.07
Market Cap	$130.02M
P/E Ratio	-2.31
P/B Ratio	3.11
P/S Ratio	2778.96
EPS (TTM)	$-1.00
52-Week High	$3.82
52-Week Low	$0.91
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-130.95%
ROA	-98.21%
ROCE	-138.10%
Gross Margin	100.00%
Operating Margin	-603.12%
Net Margin	-583.50%
Debt/Equity	0.02
Current Ratio	3.64

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$26.0M	$0
Operating Profit	$-98.0M	$-119.0M	$-69.0M	$-22.0M	$-58.0M
Net Profit	$-202.0M	$-118.0M	$-62.0M	$-16.0M	$-55.0M
EPS	$-25.00	$-14.50	$-1.08	$-0.28	$-1.00
Op Margin	—	—	—	-86.2%	-90740.6%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$291.0M	$174.0M	$127.0M	$101.0M	$56.0M
Total Liabilities	$19.0M	$17.0M	$26.0M	$9.0M	$14.0M
Cash	$268.0M	$79.0M	$106.0M	$78.0M	$38.0M
Borrowings	$0	$0	$0	$0	$1.0M

Latest News

Oppenheimer Initiates Connect Biopharma at Outperform With $8 Price Target MT Newswires · Jul 9, 2026 Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma GlobeNewswire · Jun 17, 2026 Canaccord Genuity Initiates Connect Biopharma at Buy With $6 Price Target MT Newswires · May 26, 2026 Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 MarketBeat · May 22, 2026 Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky Simply Wall St. · May 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-86.0M	$-99.0M	$-48.0M	$-24.0M	$-51.0M
Investing Cash Flow	$-13.0M	$-88.0M	$75.0M	$-4.0M	$9.0M
Financing Cash Flow	$-20.0M	$0	$0	$0	$0
Net Cash Flow	$109.0M	$-169.0M	$27.0M	$-27.0M	$-40.0M
Free Cash Flow	$-93.0M	$-104.0M	$-48.0M	$-24.0M	$-52.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-18.11%
Quick Ratio	3.74
Interest Coverage	—
Return 1Y	67.02%
Return 3Y	118.06%
Return 5Y	-89.75%

Ownership

Insiders Held31.82%

Institutions Held55.58%

Institutions Float Held81.53%

Institutional Holder	Shares	Report Date
Ikarian Capital, LLC	5,388,486	2026-03-31
Boothbay Fund Management, LLC	1,234,582	2026-03-31
683 Capital Management LLC	900,000	2026-03-31
Perceptive Advisors Llc	792,696	2026-03-31
Adar1 Capital Management, LLC	742,400	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ARTV	$11.27	-2.68%	-2.29	$278.56M	0.00%
CNTX	$0.62	+4.47%	-6.84	$56.69M	0.00%
IFRX	$1.84	+6.98%	-4.16	$132.91M	0.00%
IMA	$5.69	+1.07%	-1.49	$64.18M	0.00%
KLRS	$3.40	+1.80%	-2.86	$63.59M	0.00%

About CNTB

CNTB is led by CEO Barry D. Quart, employs 62 people, headquartered in CN, publicly traded since 2021.

CNTB stock trades at $2.07 with a market capitalization of $130.02M. The stock is valued at a price-to-earnings (P/E) ratio of -2.31, price-to-book of 3.11, price-to-sales of 2778.96. Over the past 52 weeks the stock has ranged between $0.91 and $3.82, and currently trades 45.8% below its 52-week high.

On profitability, CNTB generates a return on equity (ROE) of -130.95%, return on capital employed of -138.10%, an operating margin of -603.12%, a net profit margin of -583.50%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides